{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470601929
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = xi/o
| target = [[CD40]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 299423-37-3
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G0MV33WQ6V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06071
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Teneliximab''' is a [[chimeric protein|chimeric]] [[monoclonal antibody]]<ref>[http://whqlibdoc.who.int/druginfo/INN_2003_list49.pdf International Nonproprietary Names For Pharmaceutical Substances]</ref> binding to the immune stimulatory protein [[CD40]]. {{as of|2009}}, it has not entered [[clinical trial]]s.<ref>{{cite book|title=Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology)|editor=Iqbal S. Grewal|publisher=Springer|date=January 15, 2009|page=22|isbn=0-387-89519-1}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}